🚀 VC round data is live in beta, check it out!
Xintela Valuation Multiples
Discover revenue and EBITDA valuation multiples for Xintela and similar public comparables like Xbrane Biopharma, Lexaria Bioscience, Isofol Medical, NeuroSense Therapeutics and more.
Xintela Overview
About Xintela
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Founded
2009
HQ
Employees
13
Website
Sectors
Financials (LTM)
EV
$24M
Xintela Financials
Xintela reported last 12-month revenue of $566K and negative EBITDA of ($7M).
In the same LTM period, Xintela generated $566K in gross profit, ($7M) in EBITDA losses, and had net loss of ($7M).
Revenue (LTM)
Xintela P&L
In the most recent fiscal year, Xintela reported revenue of $253K and EBITDA of ($5M).
Xintela expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $566K | XXX | $253K | XXX | XXX | XXX |
| Gross Profit | $566K | XXX | $248K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | ($7M) | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | (1190%) | XXX | (1981%) | XXX | XXX | XXX |
| EBIT Margin | (1190%) | XXX | (2008%) | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (1239%) | XXX | (2089%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Xintela Stock Performance
Xintela has current market cap of $26M, and enterprise value of $24M.
Market Cap Evolution
Xintela's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24M | $26M | 3.7% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXintela Valuation Multiples
Xintela trades at 41.6x EV/Revenue multiple, and (3.5x) EV/EBITDA.
EV / Revenue (LTM)
Xintela Financial Valuation Multiples
As of April 18, 2026, Xintela has market cap of $26M and EV of $24M.
Equity research analysts estimate Xintela's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xintela has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26M | XXX | $26M | XXX | XXX | XXX |
| EV (current) | $24M | XXX | $24M | XXX | XXX | XXX |
| EV/Revenue | 41.6x | XXX | 93.0x | XXX | XXX | XXX |
| EV/EBITDA | (3.5x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/EBIT | (3.5x) | XXX | (4.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 41.6x | XXX | 94.8x | XXX | XXX | XXX |
| P/E | (3.7x) | XXX | (4.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Xintela Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Xintela Margins & Growth Rates
Xintela's revenue in the last 12 month grew by 83%.
Xintela's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Xintela's rule of 40 is (369%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xintela's rule of X is 272% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Xintela Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 83% | XXX | 418% | XXX | XXX | XXX |
| EBITDA Margin | (1190%) | XXX | (1981%) | XXX | XXX | XXX |
| EBITDA Growth | 158% | XXX | 108% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (369%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 272% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 75% | XXX | 162% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 401% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1031% | XXX | 1576% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2106% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Xintela Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Xintela | XXX | XXX | XXX | XXX | XXX | XXX |
| Xbrane Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexaria Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Isofol Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroSense Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistagen Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xintela M&A Activity
Xintela acquired XXX companies to date.
Last acquisition by Xintela was on XXXXXXXX, XXXXX. Xintela acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Xintela
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXintela Investment Activity
Xintela invested in XXX companies to date.
Xintela made its latest investment on XXXXXXXX, XXXXX. Xintela invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Xintela
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Xintela
| When was Xintela founded? | Xintela was founded in 2009. |
| Where is Xintela headquartered? | Xintela is headquartered in Sweden. |
| How many employees does Xintela have? | As of today, Xintela has over 13 employees. |
| Is Xintela publicly listed? | Yes, Xintela is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Xintela? | Xintela trades under XINT ticker. |
| When did Xintela go public? | Xintela went public in 2016. |
| Who are competitors of Xintela? | Xintela main competitors are Xbrane Biopharma, Lexaria Bioscience, Isofol Medical, NeuroSense Therapeutics. |
| What is the current market cap of Xintela? | Xintela's current market cap is $26M. |
| What is the current revenue of Xintela? | Xintela's last 12 months revenue is $566K. |
| What is the current revenue growth of Xintela? | Xintela revenue growth (NTM/LTM) is 83%. |
| What is the current EV/Revenue multiple of Xintela? | Current revenue multiple of Xintela is 41.6x. |
| Is Xintela profitable? | No, Xintela is not profitable. |
| What is the current EBITDA of Xintela? | Xintela has negative EBITDA and is not profitable. |
| What is Xintela's EBITDA margin? | Xintela's last 12 months EBITDA margin is (1190%). |
| What is the current EV/EBITDA multiple of Xintela? | Current EBITDA multiple of Xintela is (3.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.